EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

M C van Hooff, E Werner, A J van der Meer

European Journal of Internal Medicine · 2024-06 · 124 · 14-21

DOI: 10.1016/j.ejim.2024.01.030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2024-06. Verfasst von M C van Hooff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, NA building, Floor 6, Rotte…. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Cholagogues and Choleretics. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 123 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary biliary cholangitis (PBC) is a rare cholestatic immune-mediated liver disease. The clinical course varies from mild to severe, with a substantial group of patients developing cirrhosis within a decade. These patients are at risk of hepatocellular carcinoma, decompensation and liver failure. First line Ursodeoxycholic acid (UDCA) treatment improves the cholestatic surrogate markers, and was recently associated with a favorable survival free of liver transplantation, even in case of an incomplete biochemical response. However, despite adequate UDCA therapy, patients remain at risk of liver disease progression. Therefore, on-treatment multifactor-based risk stratification is necessary to identify patients in need of additional therapy. This requires a personalized approach; especially as recent studies suggest that complete biochemical normalization as most stringent response criterion might be preferred in selected patients to optimize their outcome. Today, stricter biochemical goals might actually be reachable with the addition of farnesoid X receptor or peroxisome proliferator-activated receptor agonists, or, in highly-selected cases, use of corticosteroids. Randomized controlled trials showed improvements in the key biochemical surrogate markers with the addition of these drugs, which have also been associated with improved clinical outcome. Considering this evolving PBC landscape, with more versatile treatment options and treatment goals, this review recapitulates the recent insight in UDCA therapy, the selection of patients with a residual risk of liver disease progression and the results of the currently available second line treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursodeoxycholic AcidLiver Cirrhosis, BiliaryCholagogues and CholereticsHumansDisease ProgressionReceptors, Cytoplasmic and NuclearRandomized Controlled Trials as TopicLiver TransplantationAdrenal Cortex HormonesPeroxisome Proliferator-Activated ReceptorsReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

BezafibrateFibratesObeticholic acidPrimary biliary cholangitisUrsodeoxycholic acid

Substanzen

Ursodeoxycholic AcidCholagogues and CholereticsReceptors, Cytoplasmic and NuclearAdrenal Cortex HormonesPeroxisome Proliferator-Activated ReceptorsReceptor, Farnesoid X-Activated

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, NA building, Floor 6, Rotterdam 3015 GD, the Netherlands.
  • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, NA building, Floor 6, Rotterdam 3015 GD, the Netherlands. Electronic address: a.vandermeer@erasmu…

Zitieren

APA

van Hooff, M. C., Werner, E., & van der Meer, A. J. (2024). Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid. European Journal of Internal Medicine, 124, 14-21. https://doi.org/10.1016/j.ejim.2024.01.030

Vancouver

van Hooff MC, Werner E, van der Meer AJ. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid. European Journal of Internal Medicine. 2024;124:14-21. doi:10.1016/j.ejim.2024.01.030

BibTeX
@article{vanHooff2024,
  author = {van Hooff, M C and Werner, E and van der Meer, A J},
  title = {Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  volume = {124},
  pages = {14--21},
  doi = {10.1016/j.ejim.2024.01.030}
}
Kostenlos starten →